Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity (original) (raw)
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
John Shaughnessy
Cytotherapy, 2011
View PDFchevron_right
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
Ken Maes
OncoImmunology
View PDFchevron_right
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Nadim Jilani
Blood, 2012
View PDFchevron_right
Lenalidomide consolidation and maintenance therapy after autologous stem cell transplantation for multiple myeloma induces persistent changes in T-cell homeostasis
Antoine Toubert
Leukemia & Lymphoma, 2013
View PDFchevron_right
Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
Sieghart Sopper
Blood Cancer J, 2013
View PDFchevron_right
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
SARA CANNITO
View PDFchevron_right
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study
Christian Ottensmeier
Cancer Immunology, Immunotherapy, 2015
View PDFchevron_right
Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma
Cristina Tresoldi
Frontiers in Immunology
View PDFchevron_right
Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens
Soudeh Ghafouri-Fard
Iranian Journal of Cancer Prevention, 2015
View PDFchevron_right
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
Dietmar Pfeifer
Leukemia Research, 2010
View PDFchevron_right
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
Kohji Itoh
PLoS ONE, 2013
View PDFchevron_right
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Sacha Gnjatic
Blood, 2006
View PDFchevron_right
immunomodulatory effects Clinical, in-vitro and in-vivo significance of JAM-A expression by clonal plasma cells in multiple myeloma patients View project Multiple myeloma: from the biology of disease overcoming drug resistance View project
Ken Maes
View PDFchevron_right
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Camille Abboud
Leukemia research, 2016
View PDFchevron_right
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
Igor Blau
Oncotarget, 2014
View PDFchevron_right
Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine
Sergei Kusmartsev
Cancer Immunology, Immunotherapy, 2010
View PDFchevron_right
In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma
Yehia S Mohamed
Frontiers in Immunology, 2019
View PDFchevron_right
Cancer-Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma
Achim Jungbluth
Cancer Immunology Research, 2014
View PDFchevron_right
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Nita Ahuja
Oncotarget, 2014
View PDFchevron_right
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma
muthu raja
Leukemia & Lymphoma, 2012
View PDFchevron_right
Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients
Vaijayanti Kale
Frontiers in Immunology
View PDFchevron_right
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study
Andrzej Jakubowiak
Journal for ImmunoTherapy of Cancer, 2020
View PDFchevron_right
Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy
Masood Shammas
Clinical Cancer Research, 2008
View PDFchevron_right
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Neha Soni
Molecular Cancer Therapeutics, 2019
View PDFchevron_right
The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myeloma
Tiffany Khong
Haematologica, 2008
View PDFchevron_right
The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma
Tiffany Khong
2008
View PDFchevron_right
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
Anne Gang
2014
View PDFchevron_right
Lenalidomide enhances the function of CS1 chimeric antigen receptor redirected T cells against multiple myeloma
Flavia Pichiorri
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017
View PDFchevron_right
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
Nicolas Blin
Leukemia, 2015
View PDFchevron_right
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse
Basem M. William
Biology of Blood and Marrow Transplantation, 2019
View PDFchevron_right
Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model
Amir Sharabi
Cancer Prevention Research, 2010
View PDFchevron_right
Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
Katia Beider
Clinical and Developmental Immunology, 2012
View PDFchevron_right
Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication
Daniel Garcia Belmonte
Bone Marrow Transplantation, 2017
View PDFchevron_right
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma Impact of HSC dose on engraftment, safety, and immune reconstitution
Giuseppe Leone
Experimental Hematology, 2000
View PDFchevron_right